Polyethylene glycol-drug ester conjugates for prolonged retention of small inhaled drugs in the lung.

[1]  F. Acevedo,et al.  Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate. , 2013, Journal of aerosol medicine and pulmonary drug delivery.

[2]  W. Couet,et al.  A preclinical pharmacokinetic modeling approach to the biopharmaceutical characterization of immediate and microsphere-based sustained release pulmonary formulations of rifampicin. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  T. Kissel,et al.  Controlled pulmonary drug and gene delivery using polymeric nano-carriers. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[4]  G. Tiram,et al.  Administration, distribution, metabolism and elimination of polymer therapeutics. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Francesco M Veronese,et al.  State of the art in PEGylation: the great versatility achieved after forty years of research. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[6]  D. Stolz,et al.  PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel. , 2012, Bioconjugate chemistry.

[7]  Ken Grime,et al.  Optimisation of DMPK by the inhaled route: challenges and approaches. , 2012, Current drug metabolism.

[8]  K. Beck,et al.  Pegylation of Antimicrobial Peptides Maintains the Active Peptide Conformation, Model Membrane Interactions, and Antimicrobial Activity while Improving Lung Tissue Biocompatibility following Airway Delivery , 2012, Antimicrobial Agents and Chemotherapy.

[9]  Zhijun Yang,et al.  Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery , 2012, International Journal of Nanomedicine.

[10]  P. Rojsitthisak,et al.  Effects of different carboxylic ester spacers on chemical stability, release characteristics, and anticancer activity of mono-PEGylated curcumin conjugates. , 2011, Journal of pharmaceutical sciences.

[11]  H. Katsumi,et al.  Development of polyethylene glycol-conjugated alendronate, a novel nitrogen-containing bisphosphonate derivative: evaluation of absorption, safety, and effects after intrapulmonary administration in rats. , 2011, Journal of pharmaceutical sciences.

[12]  K. Lee,et al.  Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[13]  Xiaoying Wang,et al.  In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[14]  K. Rabe,et al.  Comparison of exhaled breath condensate pH using two commercially available devices in healthy controls, asthma and COPD patients , 2009, Respiratory research.

[15]  D. Lechuga‐Ballesteros,et al.  Absorption of polyethylene glycol (PEG) polymers: the effect of PEG size on permeability. , 2009, Journal of pharmaceutical sciences.

[16]  Po‐Chang Chiang,et al.  Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies. , 2008, Journal of pharmaceutical sciences.

[17]  P. H. van der Graaf,et al.  A non-parametric method to analyse time-course of effect in the absence of pharmacokinetic data: application to inhaled bronchodilators. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[18]  Juliane Nguyen,et al.  Biodegradable polymeric nanocarriers for pulmonary drug delivery , 2008 .

[19]  S. Chae,et al.  Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[20]  M. K. Bayliss,et al.  A Comparison of the Expression and Metabolizing Activities of Phase I and II Enzymes in Freshly Isolated Human Lung Parenchymal Cells and Cryopreserved Human Hepatocytes , 2007, Drug Metabolism and Disposition.

[21]  M. Sakagami,et al.  In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. , 2006, Advanced drug delivery reviews.

[22]  R. Borchardt,et al.  Enzymes involved in the bioconversion of ester-based prodrugs. , 2006, Journal of pharmaceutical sciences.

[23]  Z. Su,et al.  A Simple and Efficient Method for Synthesis of Carboxymethylated Polyethyleneglycol , 2005 .

[24]  A. Morice,et al.  Exhaled breath condensate pH and exhaled nitric oxide in allergic asthma and in cystic fibrosis , 2004, Thorax.

[25]  L. Låstbom,et al.  A Novel Method to Aerosolize Powder for Short Inhalation Exposures at High Concentrations: Isolated Rat Lungs Exposed to Respirable Diesel Soot , 2004, Inhalation toxicology.

[26]  Hans Lennernäs,et al.  Drug Absorption from the Isolated Perfused Rat Lung–Correlations with Drug Physicochemical Properties and Epithelial Permeability , 2003, Journal of drug targeting.

[27]  P. Högger.  Dose response and therapeutic index of inhaled corticosteroids in asthma , 2003, Current opinion in pulmonary medicine.

[28]  R. Larsson,et al.  Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. , 2002, Respiratory medicine.

[29]  B. Gaston,et al.  Endogenous airway acidification. Implications for asthma pathophysiology. , 2000, American journal of respiratory and critical care medicine.

[30]  F. Rypáček,et al.  Solute Absorption from the Airways of the Isolated Rat Lung. V. Charge Effects on the Absorption of Copolymers of N(2-hydroxyethyl)-DL-Aspartamide with DL-Aspartic Acid or Dimethylaminopropyl-DL-Aspartamide , 1999, Pharmaceutical Research.

[31]  H. Kelly.  Establishing a therapeutic index for the inhaled corticosteroids: part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. , 1998, The Journal of allergy and clinical immunology.

[32]  C. Sorkness.  Establishing a therapeutic index for the inhaled corticosteroids: part II. Comparisons of systemic activity and safety among different inhaled corticosteroids. , 1998, The Journal of allergy and clinical immunology.

[33]  C. Lee,et al.  Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity. , 1998, Bioorganic & medicinal chemistry.

[34]  K Brendel,et al.  Human and rat lung biotransformation of cyclosporin A and its derivatives using slices and bronchial epithelial cells. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[35]  Mark Gumbleton,et al.  Challenges in inhaled product development and opportunities for open innovation. , 2011, Advanced drug delivery reviews.

[36]  J. Nguyen,et al.  Biodegradable polymeric nanocarriers for pulmonary drug delivery. , 2008, Expert opinion on drug delivery.

[37]  Peter R. Byron,et al.  Inhaling medicines: delivering drugs to the body through the lungs , 2007, Nature Reviews Drug Discovery.

[38]  D. Dodd,et al.  Two-week aerosol inhalation study on polyethylene glycol (PEG) 3350 in F-344 rats. , 1989, Drug and chemical toxicology.